Selected article for: "activation result and adaptive immune system"

Author: Kaklamanos, Aimilios; Belogiannis, Konstantinos; Skendros, Panagiotis; Gorgoulis, Vassilis G.; Vlachoyiannopoulos, Panayiotis G.; Tzioufas, Athanasios G.
Title: COVID-19 Immunobiology: Lessons Learned, New Questions Arise
  • Cord-id: 7rauhh30
  • Document date: 2021_8_26
  • ID: 7rauhh30
    Snippet: There is strong evidence that COVID-19 pathophysiology is mainly driven by a spatiotemporal immune deregulation. Both its phenotypic heterogeneity, spanning from asymptomatic to severe disease/death, and its associated mortality, are dictated by and linked to maladaptive innate and adaptive immune responses against SARS-CoV-2, the etiologic factor of the disease. Deregulated interferon and cytokine responses, with the contribution of immune and cellular stress-response mediators (like cellular s
    Document: There is strong evidence that COVID-19 pathophysiology is mainly driven by a spatiotemporal immune deregulation. Both its phenotypic heterogeneity, spanning from asymptomatic to severe disease/death, and its associated mortality, are dictated by and linked to maladaptive innate and adaptive immune responses against SARS-CoV-2, the etiologic factor of the disease. Deregulated interferon and cytokine responses, with the contribution of immune and cellular stress-response mediators (like cellular senescence or uncontrolled inflammatory cell death), result in innate and adaptive immune system malfunction, endothelial activation and inflammation (endothelitis), as well as immunothrombosis (with enhanced platelet activation, NET production/release and complement hyper-activation). All these factors play key roles in the development of severe COVID-19. Interestingly, another consequence of this immune deregulation, is the production of autoantibodies and the subsequent development of autoimmune phenomena observed in some COVID-19 patients with severe disease. These new aspects of the disease that are now emerging (like autoimmunity and cellular senescence), could offer us new opportunities in the field of disease prevention and treatment. Simultaneously, lessons already learned from the immunobiology of COVID-19 could offer new insights, not only for this disease, but also for a variety of chronic inflammatory responses observed in autoimmune and (auto)inflammatory diseases.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and active infection: 1, 2, 3
    • abdominal pain and activity number: 1
    • abdominal pain and acute ards: 1, 2, 3, 4
    • abdominal pain and acute coronary syndrome: 1
    • abdominal pain and acute inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abdominal pain and acute kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • abdominal pain and acute kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abdominal pain and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • abdominal pain and acute respiratory failure: 1, 2, 3, 4, 5, 6
    • abdominal pain and additional factor: 1
    • abdominal pain and lung disease: 1, 2, 3, 4, 5, 6, 7
    • abdominal pain and lung injury: 1, 2, 3, 4, 5
    • abdominal pain and lung involvement: 1, 2, 3, 4, 5, 6, 7
    • abdominal pain and lupus anticoagulant: 1, 2
    • abdominal pain and lupus erythematosus: 1, 2, 3, 4
    • abdominal pain and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abdominal pain and lymphocyte ratio: 1, 2, 3, 4, 5
    • abdominal pain and macrophage activation: 1, 2, 3, 4